MNCs' bid to skirt cap shot down

A demand by multinational cardiac stent manufacturers to introduce a separate category of “technologically advanced and superior quality stents” that can be priced higher has not gone down well.

Published: 06th February 2018 06:39 AM  |   Last Updated: 06th February 2018 06:39 AM   |  A+A-

By Express News Service

NEW DELHI: A demand by multinational cardiac stent manufacturers to introduce a separate category of “technologically advanced and superior quality stents” that can be priced higher has not gone down well with Indian manufacturers and health activists.  

In February 2017, India’s National Pharmaceutical Pricing Authority (NPPA) had fixed a price of `30,000 for a coronary stent—a tiny device used in angioplasty to improve blood flow in the arteries to treat blockage in the heart. The move had led to prices of stents being slashed by up to 85 per cent.
 The decision, however, also caused the withdrawal of several global stent manufacturers from the Indian market who have since then been lobbying with government bodies for a separate category of high-end stents to skirt the price cap.

The NPPA, on Monday, held a meeting with several industry representatives and civil society members to get their feedback before it decides on whether stent prices need to be reviewed this year.
“Representatives of companies like Abbot, Boston Scientific and Medtronics tried hard to pursuade the officials that high-end stents are useful in case of complex and difficult cases, but were told that an expert panel of the ministry of health and family welfare has shot down the idea,” said a source in the NPPA.

Mira Shiva of All India Drug Action Network, which has been at the forefront of the debate that led to the price capping of the medical device, said that the foreign manufacturers were pushing an idea “without any scientific basis or evidences”. Ganesh Rawat, CEO of Sahajanand Medical Techologies, an Indian manufacturer, said that Indian companies did not support the claim put forth by the manufacturers from the US and other countries.

Heart of the matter

Rs 45,000 to Rs 3 lakh was the price range of cardiac stents before price capping by the National Pharmaceutical Pricing Authority

J30,000 is the fixed price of a stent now 5-yearly price review of device has been proposed by All India Drug Action Network, instead of the proposed annual review.

Stay up to date on all the latest Nation news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

Asian Games 2018